Perrigo first-to-market with private label offering of Mucinex 1200mg DM extended-release

DUBLIN - Perrigo and its partner Allergan on Tuesday announced the launch of guaifenesin 1200mg and dextromethorphan HBr 60mg extended-release tablets, the first OTC store brand equivalent to Mucinex 1200mg DM extended-release tablets. 

 

"This is another great example of the Perrigo and Allergan teams continuing to leverage their unique capabilities in providing U.S. consumers greater savings and access to key new store brand OTC products," stated John Hendrickson, Perrigo CEO. "These new store brand products, which are equivalent to the Mucinex brand, are an important offering to our customers as they deliver the first high-quality, value alternative available in the marketplace. Allergan has been an excellent partner in developing this range of new store brand guaifenesin ER products and we look forward to launching the remaining Mucinex equivalent products for the store brand market throughout the balance of this year."

 

Mucinex 1200mg DM extended-release tablets (guaifenesin 1200mg and dextromethorphan HBr 60mg extended-release tablets) are indicated to control coughs and to break up mucus, making coughs more productive. The Mucinex 1200mg DM extended-release product produced sales of approximately $108 million through food, drug and mass merchants during the last twelve months, Perrigo reported.